Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug
Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
What's Your Reaction?
